Loading...
Guidelines recommend aspirin for the primary prevention of cardiovascular (CV) events in patients with diabetes. However, evidence supporting this recommendation is sparse. In this meta-analysis of six randomized controlled trials involving more than 10,000 patients, investigators determined the effects of aspirin (doses ranged from 100 mg every other day to 650 mg daily) in patients with diabetes but without preexisting CV disease.
Compared with placebo or no treatment, aspirin did not lower risk for major CV events (myocardial infarction, stroke, or CV death) or all-cause mortality. When outcomes were assessed individually, aspirin did not lower risk for MI, stroke, or CV death. However, after stratification by sex, aspirin substantially l…